- Home
- SABR vs LYEL Comparison
SABR vs LYEL Comparison
Compare SABR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | LYEL |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.9M | 490.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SABR | LYEL |
|---|---|---|
| Price | $1.72 | $23.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.50 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 4.9M | 76.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,866,956,000.00 | $36,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $3.40 | $16,285.34 |
| P/E Ratio | $1.17 | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $0.39 |
| 52 Week High | $3.46 | $45.00 |
Technical Indicators
Market Signals| Indicator | SABR | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 56.49 |
| Support Level | $1.45 | $21.27 |
| Resistance Level | $1.98 | $27.30 |
| Average True Range (ATR) | 0.11 | 1.70 |
| MACD | 0.01 | 0.49 |
| Stochastic Oscillator | 90.91 | 78.70 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.